The Aporia
Etzel, G. M. (2026, September 24). Trump FDA pick dodges senators’ questions on abortion, vaccines, and vaping. Washington Examiner. https://www.washingtonexaminer.com/policy/healthcare/4741505/trump-fda-pick-dodges-senators-questions-on-abortion-vaccines-and-vaping/
Etzel, Gabrielle M. “Trump FDA pick dodges senators’ questions on abortion, vaccines, and vaping.” Washington Examiner, 24 Sept. 2026, https://www.washingtonexaminer.com/policy/healthcare/4741505/trump-fda-pick-dodges-senators-questions-on-abortion-vaccines-and-vaping/.
Etzel, Gabrielle M. “Trump FDA pick dodges senators’ questions on abortion, vaccines, and vaping.” Washington Examiner, September 24, 2026. https://www.washingtonexaminer.com/policy/healthcare/4741505/trump-fda-pick-dodges-senators-questions-on-abortion-vaccines-and-vaping/.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Dr. Heidi Overton, President Donald Trump’s nominee to head the Food and Drug Administration (FDA), faced intense questioning from Senate lawmakers on September 24 regarding her stance on vaccines, abortion pills like mifepristone, and other contentious health issues. Senators, particularly Republicans like Sen. Bill Cassidy of Louisiana, focused heavily on Overton’s views on restricting access to the abortion pill mifepristone, which has been approved by the FDA since 2000 despite recent efforts to tighten regulations under conservative pressure.
During her confirmation hearing before the Senate Health, Education, Labor and Pensions Committee, Overton often dodged direct questions about specific policies, citing technical aspects of her potential role as commissioner. This approach upset both Democrats and Republicans who wanted more definitive answers on issues such as vaccine safety and abortion access. For instance, Sen. Chris Murphy criticized Overton for avoiding straightforward responses.
The hearing was marked by concerns over the FDA's oversight under Trump’s administration, including an executive order signed in August 2025 calling for splitting up the combined MMR vaccine into three separate shots—a move based on misinformation about vaccine safety. Despite these controversies, Overton maintained that “the MMR vaccine is currently licensed and approved by the FDA,” highlighting its importance during a significant measles outbreak with four deaths reported in Pennsylvania in 2026 due to low vaccination rates.